Aciphex Tablet, Delayed Release
Product Images NDC 80725-243

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Aciphex (NDC 80725-243). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Waylis Therapeutics Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Aciphex 01)

Chemical structure of rabeprazole sodium, the active ingredient in Aciphex 20 mg delayed-release tablets. The diagram shows the molecular arrangement including sulfur, nitrogen, sodium, oxygen, and other atoms typical of the rabeprazole sodium compound.*

FDA Label Image

Figure 2 (Aciphex 02)

A line graph depicting mean heartburn scores over a 28-day study period for three groups: placebo, rabeprazole 10 mg, and rabeprazole 20 mg. The x-axis shows study days from -14 to 28, and the y-axis represents mean heartburn scores from 0 (none) to 4 (very severe). The graph shows a notable decrease in heartburn scores after day 0 for both rabeprazole groups compared to placebo.*

FDA Label Image

Figure 3 (Aciphex 03)

A line graph showing mean heartburn scores over a 28-day study period comparing placebo, rabeprazole 10 mg, and rabeprazole 20 mg groups. The y-axis represents mean heartburn scores on a scale from 0 (none) to 4 (very severe), and the x-axis shows study days from -14 to 28. The graph illustrates changes in heartburn severity before and after the start of treatment at day 0 for each group.*

FDA Label Image

Figure 4 (Aciphex 04)

A line graph showing mean heartburn scores over time from 14 days before to 28 days after starting treatment (study day 0). Two treatment groups are compared: placebo (n=58) and rabeprazole sodium 20 mg (n=59). The graph illustrates decreasing heartburn severity in the 20 mg rabeprazole group compared to placebo over the study period.*

FDA Label Image

Figure 5 (Aciphex 05)

A line graph comparing mean heartburn scores over study days for a placebo group and a rabeprazole 20 mg group. The x-axis shows study days ranging from -14 to 28, and the y-axis shows mean scores from 0 (none) to 4 (very severe). The rabeprazole group consistently has lower mean heartburn scores after day 0 compared to placebo.*

FDA Label Image

Principal Display Panel (30 Tablet Bottle Label)

Label for AcipHex rabeprazole sodium delayed-release tablets, 20 mg strength, oral dosage form. The label shows the product name, strength, and 30 tablets count. It includes storage instructions, distributor Waylis Therapeutics LLC, and NDC 80725-243-30.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.